Biogen (BIIB) PT Raised to $455 at Guggenheim
Get Alerts BIIB Hot Sheet
Price: $201.48 +4.30%
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja raised the price target on Biogen (NASDAQ: BIIB) to $455.00 (from $325.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biogen (BIIB) tops earnings expectations but revenue falls short
- Bernstein SocGen Group Upgrades CapCom Co Ltd. (9697:JP) (CCOEY) to Outperform
- BMO Capital First Take on Biogen (BIIB) Earnings
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!